Evolus Inc. (EOLS)
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago.
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Rui Avelar - Chief Medical Officer and Head of R&D Conference Call Participants Jack Padovano - Stifel Navann Ty - BNP Serge Belanger - Needham & Company Operator Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quarter 2024 Earnings Conference Call.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.22 per share a year ago.
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau.
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Medical aesthetics company Evolus notched its first-ever profits late Wednesday — two quarters ahead of expectations.
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
